Novozymes A/S NSIS-B.CO
Composite 51/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 16/100 — a strong mark against it.
Growth ranks 75/100 — a strong point in its favour. Momentum ranks 70/100 — a moderate point in its favour. Balance-sheet strength ranks 62/100 — a slight point in its favour.
Valuation ranks 16/100 — a strong mark against it. Quality ranks 42/100 — a slight mark against it.
What the company does Novozymes A/S develops and sells industrial enzymes, functional proteins, and microorganisms for food, beverage, bioenergy, cleaning, and human health applications across global markets.
Key financials Gross margin is 55.9%, operating margin 24.4%, and net margin 14.2%. ROE is 5.4%, ROA 3.8%, and ROCE -1.0%. Revenue grew 3.9% and EPS 7.5%, with forward P/E at 26.45 and PEG at 0.41.
Stock health Sideravia scores the stock Weak quality (41.7) and richly valued (15.8), with overall 39.1/100. Debt/Equity is 0.29, net debt/EBITDA 1.87, and interest coverage -2.20. Piotroski F-Score is 6/9 and Altman Z is 22.05.
Price vs fair value The stock trades at a PREMIUM of 43.30% versus our fair-value estimate of 236.95 and at a discount of 11.52% versus the analyst 12-month target of 466.06. - Forward P/E of 26.45 vs trailing 43.59 (Valuation) - PEG of 0.41 signals undervaluation vs P/E of 43.59 (Valuation) - EBITDA multiple of 34.67x is high vs peers (Valuation) - Net margin 14.2% lags growth in revenue and EPS (Profitability) - RSI(14) at 52.50 indicates neutral momentum (Momentum)
Looking forward Analysts expect 12-month upside to 466.06, but weak quality scores and high multiples cap near-term valuation support. Growth in bioenergy and human health segments may drive future margin expansion.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.